SUPERNUS PHARMACEUTICALS, INC. Deferred Tax Liabilities, Leasing Arrangements
SUPERNUS PHARMACEUTICALS, INC. (SUPN) had Deferred Tax Liabilities, Leasing Arrangements of $6.66 million as of 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Liabilities, Net › Deferred Tax Liabilities, Gross
us-gaap:DeferredTaxLiabilitiesLeasingArrangements · last filed 2026-03-02
- 2025-12-31: Deferred Tax Liabilities, Leasing Arrangements $6.66M.
- 2024-12-31: Deferred Tax Liabilities, Leasing Arrangements $6.16M.
- 2023-12-31: Deferred Tax Liabilities, Leasing Arrangements $7.25M.
- 2022-12-31: Deferred Tax Liabilities, Leasing Arrangements $7.34M.
| Period end | Deferred Tax Liabilities, Leasing Arrangements |
|---|---|
| 2025-12-31 | $6.66M 10-K · filed 2026-03-02 |
| 2024-12-31 | $6.16M 10-K · filed 2026-03-02 |
| 2023-12-31 | $7.25M 10-K · filed 2025-02-25 |
| 2022-12-31 | $7.34M 10-K · filed 2023-03-09 |
| 2021-12-31 | $9.10M 10-K · filed 2023-03-09 |
| 2020-12-31 | $10.67M 10-K · filed 2022-04-13 |
| 2019-12-31 | $5.24M 10-K · filed 2021-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |